Pharmacokinetics of kemantane in rats

Boiko, S. S.; Zherdev, V. P.; Dvoryaninov, A. A.; Jankü, I; Buchar, E.

doi:10.1007/bf00841308

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dry residue was stored at -20 о С. Then, the residues were dissolved in 1 ml eluent and chromatographic evaluation was performed as described before [1]. CPG content was calculated using the absolute calibration approach.…”

Section: Methodsmentioning

confidence: 99%

Regional and Subcellular Localization of Cycloprolylglycine in Rat Brain

et al. 2010

Self Cite

View full text Add to dashboard Cite

HPLC analysis showed that endogenous cyclopeptide cycloprolylglycine exhibiting mnemotropic and anxiolytic properties is nonuniformly distributed between brain structures in rats: its contents in the whole brain, cortex, and hippocampus were 29.2±1.6, 38.9±8.0, 126.4±32.4 nmol/g, respectively. Cycloprolylglycine distribution between subcellular fractions of brain neurons is also nonuniform: 60% cyclopeptide appeared in the nuclear fraction.

show abstract

Section: Methodsmentioning

confidence: 99%

Regional and Subcellular Localization of Cycloprolylglycine in Rat Brain

et al. 2010

Self Cite

View full text Add to dashboard Cite

show abstract

“…The schedule of the experimental study of the pharmacokinetics upon intravenous (5 mg/kg) and peroral (50 mg/kg) administration of the parent drug in rats was described elsewhere [3,4]. In this study, the pharmacokinetics and bioaccessibility of noopept in a ready-to-use drug form was evaluated for the drug in the form of a tabletization mixture administered intragastrically in a dose of 70 mg/kg.…”

Section: Experimental Partmentioning

confidence: 99%

“…Previously, the drug was characterized with respect to pharmacokinetics upon intravenous and peroral administration in rats [3,4]. The results showed that noopept is rapidly metabolized upon intravenous injection, as manifested by a pronounced effect of the "first passage" through liver upon peroral administration.…”

mentioning

confidence: 99%

“…The blood samples were taken from the edge auricular 5, 10, 20, 30, 45, 60 and 90 min after drug administration. The samples were collected in tubes containing 250 units of heparin.Subsequent processing of the blood samples, chromatographic analysis, and calculation of the pharmacokinetic parameters were performed as described in [3,4]. The drug pharmacokinetics was characterized by a set of parameters calculated within the framework of a model-independent method, including the maximum concentration (C max ), the time to maximum concentration (T max ), the area under the pharmacokinetic (concentration versus time) curve (AUC 0 ® ¥ ), the mean absorption time (MAT ) and mean retention time (MRT ) of the drug in the organism, the half-elimination time (T 1/2 ), and the elimination rate constant (K el ).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Bioaccessibility of the new dipeptide nootropic drug noopept

et al. 2004

Self Cite

View full text Add to dashboard Cite

Noopept, or N-phenylacetyl-L-prolylglycine ethyl ester, is a new dipeptide drug possessing pronounced nootropic properties [1,2]. Previously, the drug was characterized with respect to pharmacokinetics upon intravenous and peroral administration in rats [3,4]. The results showed that noopept is rapidly metabolized upon intravenous injection, as manifested by a pronounced effect of the "first passage" through liver upon peroral administration.The aim of this study was to assess the absolute and relative bioaccessibility of noopept administered in various forms in rats and rabbits. EXPERIMENTAL PARTThe experiments were performed on white mongrel male rats weighing 180 -250 g and on chinchilla rabbits weighing 3.0 -3.8 kg. The schedule of the experimental study of the pharmacokinetics upon intravenous (5 mg/kg) and peroral (50 mg/kg) administration of the parent drug in rats was described elsewhere [3,4]. In this study, the pharmacokinetics and bioaccessibility of noopept in a ready-to-use drug form was evaluated for the drug in the form of a tabletization mixture administered intragastrically in a dose of 70 mg/kg. The animals were decapitated with discrete time intervals after treatment, and the blood for analyses was collected in heparin-treated tubes.The study of the noopept pharmacokinetics in rabbits was carried out as follows. The control samples of blood were taken from the edge auricular veins of all animals di-vided into three groups. Then, rabbits in the first group were treated by the parent substance of noopept (10 mg/kg) injected into edge auricular veins; animals in the second group received the drug in a dose of 50 mg/kg introduced in a volume of 8 ml via a gastric tube; and animals in the third group received uncrushed tablets with the same volume of water. The blood samples were taken from the edge auricular 5, 10, 20, 30, 45, 60 and 90 min after drug administration. The samples were collected in tubes containing 250 units of heparin.Subsequent processing of the blood samples, chromatographic analysis, and calculation of the pharmacokinetic parameters were performed as described in [3,4]. The drug pharmacokinetics was characterized by a set of parameters calculated within the framework of a model-independent method, including the maximum concentration (C max ), the time to maximum concentration (T max ), the area under the pharmacokinetic (concentration versus time) curve (AUC 0 ® ¥ ), the mean absorption time (MAT ) and mean retention time (MRT ) of the drug in the organism, the half-elimination time (T 1/2 ), and the elimination rate constant (K el ). In addition, we calculated the ratio of the maximum concentration to the area under the pharmacokinetic curve (C max /AUC 0 ® ¥ ), which characterizes the rate of drug absorption, and determined the absolute bioaccessibility (defined as AUC p.o. /AUC i.v. for the parent substance) and the relative bioaccessibility (defined as AUC tabl /AUC par ) of the drug studied. The experimental data were statistically processed on a computer using an SPSS 9.0.0...

show abstract

“…Previously, we have studied the pharmacokinetics of noopept in rats upon intravenous injection of an aqueous solution of the parent substance in a dose of 5 mg/kg [3].…”

mentioning

confidence: 99%

Noopept pharmacokinetics after intravenous administration of a lyophilized medicinal form in rats

et al. 2007

Self Cite

View full text Add to dashboard Cite

The pharmacokinetics of noopept, a dipeptide drug possessing nootropic and neuroprotective properties, were evaluated in rats after the intravenous administration of its novel formulation for injections prepared using lyophilization in the presence of mannitol. The pharmacokinetic characteristics of the new preparation are comparable with those of aqueous solutions of the parent substance and can be recommended for further investigation and implementation into medical practice.

show abstract

Pharmacokinetics of kemantane in rats

Cited by 4 publications

References 0 publications

Regional and Subcellular Localization of Cycloprolylglycine in Rat Brain

Regional and Subcellular Localization of Cycloprolylglycine in Rat Brain

Bioaccessibility of the new dipeptide nootropic drug noopept

Noopept pharmacokinetics after intravenous administration of a lyophilized medicinal form in rats

Contact Info

Product

Resources

About